Suzanne Gokool

Suzanne Gokool

Auto-generated profile, based on publicly available information

Suzanne Gokool

UKHSA, United Kingdom Health Security Agency, London, United Kingdom

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2016 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
WVWesley C Van Voorhis
Wesley C Van Voorhis
JAJohn H Adams
John H Adams
RARoberto Adelfio
Roberto Adelfio
VAVida Ahyong
Vida Ahyong
MAMyles H Akabas
Myles H Akabas
PWPaul A Willis
Paul A Willis
A major cause of the paucity of new starting points for drug discovery is the lack of interaction between academia and industry. Much of the global resource in biology is present in universities, whereas the focus of medicinal chemistry is still largely within industry. Open source drug discovery, with sharing of information, is clearly a first step towards overcoming this gap. But the interface could especially be bridged through a scale-up of open sharing of physical compounds, which would accelerate the finding of new starting points for drug discovery. The Medicines for Malaria Venture Malaria Box is a collection of over 400 compounds representing families of structures identified in phenotypic screens of pharmaceutical and academic libraries against the Plasmodium falciparum malaria parasite. The set has now been distributed to almost 200 research groups globally in the last two years, with the only stipulation that information from the screens is deposited in the public domain. This paper reports for the first time on 236 screens that have been carried out against the Malaria Box and compares these results with 55 assays that were previously published, in a format that allows a meta-analysis of the combined dataset. The combined biochemical and cellular assays presented here suggest mechanisms of action for 135 (34%) of the compounds active in killing multiple life-cycle stages of the malaria parasite, including asexual blood, liver, gametocyte, gametes and insect ookinete stages. In addition, many compounds demonstrated activity against other pathogens, showing hits in assays with 16 protozoa, 7 helminths, 9 bacterial and mycobacterial species, the dengue fever mosquito vector, and the NCI60 human cancer cell line panel of 60 human tumor cell lines. Toxicological, pharmacokinetic and metabolic properties were collected on all the compounds, assisting in the selection of the most promising candidates for murine proof-of-concept experiments and medicinal chemistry programs. The data for all of these assays are presented and analyzed to show how outstanding leads for many indications can be selected. These results reveal the immense potential for translating the dispersed expertise in biological assays involving human pathogens into drug discovery starting points, by providing open access to new families of molecules, and emphasize how a small additional investment made to help acquire and distribute compounds, and sharing the data, can catalyze drug discovery for dozens of different indications. Another lesson is that when multiple screens from different groups are run on the same library, results can be integrated quickly to select the most valuable starting points for subsequent medicinal chemistry efforts. Malaria leads to the loss of over 440,000 lives annually; accelerating research to discover new candidate drugs is a priority. Medicines for Malaria Venture (MMV) has distilled over 25,000 compounds that kill malaria parasites in vitro into a group of 400 representative compounds, called the "Malaria Box". These Malaria Box sets were distributed free-of-charge to research laboratories in 30 different countries that work on a wide variety of pathogens. Fifty-five groups compiled >290 assay results for this paper describing the many activities of the Malaria Box compounds. The collective results suggest a potential mechanism of action for over 130 compounds against malaria and illuminate the most promising compounds for further malaria drug development research. Excitingly some of these compounds also showed outstanding activity against other disease agents including fungi, bacteria, other single-cellular parasites, worms, and even human cancer cells. The results have ignited over 30 drug development programs for a variety of diseases. This open access effort was so successful that MMV has begun to distribute another set of compounds with initial activity against a wider range of infectious agents that are of public health concern, called the Pathogen Box, available now to scientific labs all over the world (www.PathogenBox.org).

1 December 2021 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
Marc Peter HübnerMarc Peter Hübner
Marc Peter Hübner
STSimon Townson
Simon Townson
SGSuzanne Gokool
Suzanne Gokool
STSenyo Tagboto
Senyo Tagboto
MMMary J. Maclean
Mary J. Maclean
DKDaniel Kulke
Daniel Kulke
Filariae are vector-borne nematodes responsible for an enormous burden of disease. Human lymphatic filariasis, caused by Wuchereria bancrofti, Brugia malayi, and Brugia timori, and onchocerciasis (caused by Onchocerca volvulus) are neglected parasitic diseases of major public health significance in tropical regions. To date, therapeutic efforts to eliminate human filariasis have been hampered by the lack of a drug with sufficient macrofilaricidal and/or long-term sterilizing effects that is suitable for use in mass drug administration (MDA) programs, particularly in areas co-endemic with Loa loa, the causative agent of loiasis.

1 August 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SGSuzanne Gokool
Suzanne Gokool
The sorting of membrane-bound proteins from the trans-Golgi network to lysosomal/endosomal compartments is achieved by preferential inclusion into clathrin-coated vesicles. Contained within the cytoplasmic domains of such proteins, specific sequence motifs have been identified (tyrosine-based and/or di-leucine-based) that are essential for targeting and are recognized by a family of heterotetrameric adaptor complexes, which then recruit clathrin. These cytosolic protein complexes, which have been found in a wide variety of higher eukaryotic organisms, are essential for the development of multicellular organisms. In trypanosomatids, the adaptin-mediated sorting of proteins is largely uncharacterized. In order to identify components of the adaptor-complex machinery, this study reports the cloning and characterization of σ1- and μ1-adaptin gene homologues from the eukaryotic protozoan parasite, Leishmania mexicana. Generation of σ1- and μ1-adaptin gene deletion mutants shows that these promastigote parasites are viable in culture, but are unable to establish infection of macrophages or mice, indicating that adaptin function is crucial for pathogenesis in these unicellular organisms.

23 June 2022 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
NHNatalie Hawryluk
Natalie Hawryluk
LZLi Zhiru
Li Zhiru
CCClotilde Carlow
Clotilde Carlow
SGSuzanne Gokool
Suzanne Gokool
STSimon Townson
Simon Townson
ISIvan Scandale
Ivan Scandale
Filarial diseases, including lymphatic filariasis and onchocerciasis, are considered among the most devastating of all tropical diseases, affecting over 86 million people worldwide. To control and more rapidly eliminate onchocerciasis requires treatments that target the adult stage of the parasite. Drug discovery efforts are challenged by the lack of preclinical animal models using the human-pathogenic filariae, requiring the use of surrogate parasites for Onchocerca volvulus for both ex vivo and in vivo evaluation. Herein, we describe a platform utilizing phenotypic ex vivo assays consisting of the free-living nematode Caenorhabditis elegans, microfilariae and adult filariae of the bovine filariae Onchocerca lienalis and Onchocerca gutturosa, respectively, as well as microfilariae and adult filariae of the feline filariae Brugia pahangi, the rodent filariae Litomosoides sigmodontis and the human-pathogenic filariae Brugia malayi to assess activity across various surrogate parasites. Utilization of those surrogate nematodes for phenotypic ex vivo assays in order to assess activity across various parasites led to the successful establishment of a screening cascade and identification of multiple compounds with potential macrofilaricidal activity and desirable physicochemical, MW = 200–400 and low lipophilicity, logP <4, and pharmacokinetic properties, rat and human liver S9 stability of ≥70% remaining at 60 min, and AUC exposures above 3 μM h. This platform demonstrated the successful establishment of a screening cascade which resulted in the discovery of potential novel macrofilaricidal compounds for futher drug discovery lead optimization efforts. This screening cascade identified two distinct chemical series wherein one compound produced a significant 68% reduction of adult Litomosoides sigmodontis in the mouse model. Successful demonstration of efficacy prompted lead optimization medicinal chemistry efforts for this novel series.

24 February 2025
Verified
Journal Article
Open access
ATAmy C Thomas
Amy C Thomas
SGSuzanne Gokool
Suzanne Gokool
GCGenevieve Clapp
Genevieve Clapp
HWHarry Whitlow
Harry Whitlow
CMCarmel McGrath
Carmel McGrath
EBEllen Brooks-Pollock
Ellen Brooks-Pollock
The Avian Contact Study is a cross-sectional questionnaire of poultry workers and other individuals who have contact with domestic and/or wild birds in the UK. The questionnaire was launched online in May 2024 and in-person responses were gathered at the British Pig and Poultry Fair in Birmingham on 15 and 16 May 2024. This Data Note documents questionnaire development, content and delivery methods. Data collected include information on demographics, seasonal influenza vaccination, avian influenza exposure, contact with birds and people, and awareness of avian influenza. This Data Note provides insights into the first data release collected up to 31 July 2024 for 225 respondents. Data have been released as a University of Bristol held dataset available upon request. The Avian Contact Study provides a pilot resource for research into avian influenza from a zoonotic perspective.

17 October 2024 in Wellcome Open Research
Verified
Journal Article
Open access
ATAmy C. Thomas
Amy C. Thomas
SGSuzanne Gokool
Suzanne Gokool
GCGenevieve Clapp
Genevieve Clapp
HWHarry Whitlow
Harry Whitlow
CMCarmel McGrath
Carmel McGrath
EBEllen Brooks-Pollock
Ellen Brooks-Pollock
The Avian Contact Study is a cross-sectional questionnaire of poultry workers and other individuals who have contact with domestic and/or wild birds in the UK. The questionnaire was launched online in May 2024 and in-person responses were gathered at the British Pig and Poultry Fair in Birmingham on 15 and 16 May 2024. This Data Note documents questionnaire development, content and delivery methods. Data collected include information on demographics, seasonal influenza vaccination, avian influenza exposure, contact with birds and people, and awareness of avian influenza. This Data Note provides insights into the first data release collected up to 31 July 2024 for 225 respondents. Data have been released as a University of Bristol held dataset available upon request. The Avian Contact Study provides a pilot resource for research into avian influenza from a zoonotic perspective.